

Data Sharing Statement

Jastreboff AM, Kaplan LM, Frías JP, et al. Phase 2 Trial of the Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. DOI: 10.1056/NEJMoa2301972.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	—
Additional information about data	Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance. No expiration date of data requests is currently set once they are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment for up to 2 years per proposal. For details on submitting a request, see the instructions provided at vivli.org
How or where can the data be obtained?	www.vivli.org
When will data availability begin?	6 months after retatrutide has been approved for the treatment of obesity in the US and EU
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—

When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on June 26, 2023, at [NEJM.org](https://www.nejm.org).